Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
  • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/42—Phosphorus; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the present invention involves the formulation of powders which, when dissolved in water, form a liquid composition supersaturated with calcium and phosphate ions.
• the liquid composition can be used as an oral rinse for the prevention and treatment of inflammation of the soft tissues of the oral cavity, which may result from infection or trauma to the oral mucosal tissue, or for the prevention or treatment of xerostomia or chronic hyposalivation or complications therefrom.
• Saliva is made up of many inorganic and organic components, including electrolytes, proteins, immunoglobulins, enzymes, mucins, urea, and ammonia.
• the inorganic components include sodium bicarbonate, which aids in the buffering capacity of saliva.
• Saliva also includes calcium and phosphate ions in supersaturated states which allow for the maintenance of tooth mineral integrity and promotion of soft tissue healing. It is believed that calcium plays a role in preventing oral infection, protecting the oral mucosa and healing wounds in the mouth. Phosphate helps to modulate pH balance in the mouth, protecting the teeth and repairing mucosal damage.
• NeutraSal® powder is a commercially available product manufactured by Invado Pharmaceutical, LLC. It is indicated for the dryness of the mouth (hyposalivation, xerostomia); dryness of the oral mucosa due to drugs such as antihistamines or atropine or other anticholinergic agents that suppress salivary secretion; and as part of an oral hygiene program for patients with dry mouth. Relief of dryness of the oral mucosa in these conditions is associated with amelioration of pain.
• the NeutraSal® product that has been provided commercially is a powder containing about calcium chloride dihydrate, sodium chloride, sodium phosphate salts, and sodium bicarbonate.
• the commercial product is provided in packets containing 538 mg of powder, and the directions state that the powder should be mixed in 30 ml of tap, distilled or purified water, thereby forming a liquid that is supersaturated with both calcium and phosphate ions.
• the NeutraSal® powder contains a theoretical concentration of calcium ions between 20,000 and 25,000 ppm and a theoretical concentration of phosphate ions (as phosphate) between 45,000 and 60,000 ppm (calculated based on the weight percentage of each component of the dry power).
• Caphosol® is a commercially available product from jazz Pharmaceuticals that provides an electrolyte solution as a mouth rinse to moisten, lubricate and clean the oral cavity including the mucosa of the mouth, tongue and throat.
• Caphosol® is said to contain dibasic sodium phosphate 0.032% w/w, monobasic sodium phosphate 0.009% w/w, calcium chloride 0.052% w/w, sodium chloride 0.569% w/w, and purified water qs ad.
• Caphosol® is not provided as a powder; instead it is provided in two separately packaged aqueous solutions, a phosphate solution (Caphosol A) and a calcium solution (Caphosol B) which, when both ampule solutions are combined in equal volumes, form a solution supersaturated with respect to both calcium and phosphate ions.
• the present invention provides a composition useful for treating oral injury, oral inflammation, or oral pain.
• the present invention employs comprises calcium glycerophosphate, calcium lactate gluconate, or a mixture thereof.
• a powder is adapted for producing a liquid composition for treating oral injury, oral inflammation and/or oral pain.
• the powder comprises calcium glycerophosphate or calcium lactate gluconate; a sodium phosphate; and sodium chloride.
• the powder can comprise calcium glycerophosphate in an amount at least about 5% w/w and at most 25% w/w of the powder, and/or the powder can comprise dibasic sodium phosphate anhydrous, present in an amount at least about 0.5% w/w and at most about 10% w/w of the powder, and/or monobasic sodium phosphate anhydrous, present in an amount at least about 0.3% w/w and at most about 6% w/w of the powder.
• powder comprises at least 20,000 ppm calcium ions; at least 60,000 ppm phosphate ions, calculated based on weight percentages of solid components in the powder.
• the powder comprises a pH buffering agent such as sodium bicarbonate, a liquid composition prepared from the powder has a pH between about 6.5 and about 7.5.
• a method for treating a subject having an oral cavity comprises mixing a powder as described herein with water to form a liquid composition; admitting the liquid composition into the oral cavity of the subject, wherein the subject is in need of treatment for one or more of oral injury, oral inflammation, or oral pain; moving the composition within the oral cavity; and expelling the composition from the oral cavity of the subject.
• a liquid composition for use in preventing or treating oral injury, oral inflammation and/or oral pain.
• the liquid composition can also be used for preventing or treating xerostomia or chronic hyposalivation or complications from hyposalivation.
• the liquid composition is supersaturated in calcium ions and phosphate ions.
• the liquid composition is essentially free of visible particles or precipitates.
• the liquid composition is the product of mixing a powder as described herein, in a weight ratio of powder to water include from about 0.005: 1 about 0.1: 1. DETAILED DESCRIPTION
• the present disclosure is based in part on a desire for a product that is easy to manufacture, store, and use in the treatment of oral injury, oral inflammation, and/or relief of pain in the oral cavity.
• Liquid compositions are provided for treating oral injury, oral inflammation and/or oral pain by administering such compositions to a subject in need of treatment. It is known that human saliva is normally supersaturated with respect to calcium and phosphate.
• the oral rinse created by the powders contain significantly higher concentrations of calcium and phosphate ions than normally found in saliva.
• the resulting liquid composition may be supersaturated with calcium and phosphate ions in the order of 10, 100 or more times those found in normal human saliva.
• the present invention can be provided as a powder containing a mixture of calcium glycerophosphate or calcium lactate gluconate, monobasic and dibasic phosphate salts, one or more pH buffering agents, particularly sodium bicarbonate, sodium chloride and optionally xylitol.
• the powder can also contain silica and/or other components.
• a suitable amount of water is added to such powders, for example, in a powder to water weight ratio of about 0.018 to about 1, the powder will dissolve rapidly to create a liquid composition supersaturated with respect to calcium and phosphate ions and having a pH in the range of about 6.5 to about 7.5, alternatively between about 7 and about 7.4.
• the present invention can also be provided as the liquid composition prepared from such a powder.
• the present liquid compositions or powders can also comprise solutes found naturally occurring in saliva, analgesics, flavoring, preservatives, a fluoride salt or fluoride ions, a strontium salt or strontium ions, and/or a hydrophilic polymer.
• the present liquid compositions or powders can also comprise one or more preservatives, analgesics, antihistamines, corticosteroids, anti-microbial agents, and/or anti-fungal agents.
• the components of the powder are preferably food-grade ingredients.
• calcium glycerophosphate or calcium lactate gluconate or a mixture thereof is at least about 5% w/w, alternatively at least about 6% w/w, alternatively at least about 7% w/w, alternatively at least about 8% w/w, alternatively at least about 9% w/w, alternatively at least about 10% w/w, alternatively at least about 11% w/w, alternatively at least about 12% w/w, alternatively at least about 13% w/w, alternatively at least about 14% w/w, alternatively at least about 15% w/w, of the powder.
• the calcium glycerophosphate or calcium lactate gluconate or a mixture thereof is at most about 25% w/w, alternatively at most about 24% w/w, alternatively at most about 23% w/w, alternatively at most about 22% w/w, alternatively at most about 21% w/w, alternatively at most about 20% w/w, alternatively at most about 19% w/w, alternatively at most about 18% w/w, alternatively at most about 17% w/w, alternatively at most about 16% w/w, alternatively at most about 15% w/w, of the powder.
• maxima and minima may be combined to form a range, so long as the minimum is less than the maximum.
• calcium glycerophosphate or calcium lactate gluconate is present in the powder in an amount corresponding to a calcium ion concentration of at least 1,000 ppm, alternatively at least 2,000 ppm, alternatively at least 5,000 ppm, alternatively at least 10,000 ppm, alternatively at least 15,000 ppm, alternatively at least 20,000 ppm, alternatively at least or at most 22,000 ppm, alternatively at least or at most 25,000 ppm, alternatively at least or at most 30,000 ppm, alternatively at most 40,000 ppm.
• the calcium ion concentration is calculated based on weight percentages of solid components in the powder. The foregoing maxima and minima may be combined to form a range, so long as the minimum is less than the maximum.
• Suitable phosphate salts may include sodium phosphates (such as dibasic sodium phosphate anhydrous and monobasic sodium phosphate anhydrous), potassium phosphates, potassium citrate, and others.
• the phosphate salt(s) is present in the powder in an amount corresponding to a phosphate ion concentration of at least 5,000 ppm, alternatively at least 10,000 ppm, alternatively at least 20,000 ppm, alternatively at least 50,000 ppm, alternatively at least 60,000 ppm, alternatively at least or at most 65,000 ppm, alternatively at least or at most 70,000 ppm, alternatively at least or at most 75,000 ppm, alternatively at least or at most 80,000 ppm, alternatively at most 90,000 ppm.
• the phosphate ion concentration is calculated based on weight percentages of solid components in the powder. The foregoing maxima and minima may be combined to form a range, so long as the minimum is less than the maximum.
• dibasic sodium phosphate anhydrous is at least about 0.5% w/w, alternatively at least about 0.7% w/w, alternatively at least about 1% w/w, alternatively at least about 1.1% w/w, alternatively at least about 1.2% w/w, alternatively at least about 2% w/w, alternatively at least about 2.5% w/w, alternatively at least about 4% w/w, of the powder.
• dibasic sodium phosphate anhydrous is at most about 10% w/w, alternatively at most about 7.5% w/w, alternatively at most about 6% w/w, alternatively at most about 5% w/w, alternatively at most about 4% w/w, alternatively at most about 3.25% w/w, alternatively at most about 3% w/w, alternatively at most about 2.5% w/w, alternatively at most about 2% w/w, alternatively at most about 1.5% w/w, of the powder.
• the foregoing maxima and minima may be combined to form a range, so long as the minimum is less than the maximum.
• monobasic sodium phosphate anhydrous is at least about 0.3% w/w, alternatively at least about 0.5% w/w, alternatively at least about 0.6% w/w, alternatively at least about 0.7% w/w, alternatively at least about 0.8% w/w, alternatively at least about 0.9% w/w, alternatively at least about 1% w/w, alternatively at least about 1.5% w/w, alternatively at least about 2% w/w, alternatively at least about 2.5% w/w, alternatively at least about 3% w/w, of the powder.
• monobasic sodium phosphate anhydrous is at most about 6% w/w, alternatively at most about 5% w/w, alternatively at most about 4% w/w, alternatively at most about 3.5% w/w, alternatively at most about 3% w/w, alternatively at most about 2.5% w/w, alternatively at most about 2% w/w, alternatively at most about 1.5% w/w, alternatively at most about 1% w/w, alternatively at most about 0.9% w/w, alternatively at most about 0.85% w/w, of the powder.
• maxima and minima may be combined to form a range, so long as the minimum is less than the maximum.
• sodium bicarbonate or another pH buffering agent is included in the powder.
• the pH buffering agent preferably sodium bicarbonate
• sodium bicarbonate can be at most about 9% w/w, alternatively at most about 8.5% w/w, alternatively at most about 8% w/w, alternatively at most about 7.5% w/w, alternatively at most about 7% w/w, alternatively at most about 6.5% w/w, alternatively at most about 6% w/w, alternatively at most about 5 .5% w/w, alternatively at most about 5% w/w, alternatively at most about 4.9% w/w, alternatively at most about 4.5% w/w, of the powder.
• maxima and minima may be combined to form a range, so long as the minimum is less than the maximum.
• Suitable analgesics include benzocaine, lidocaine, tetracaine, hexylcaine, bupivacaine, proparacaine, prilocaine, benoxinate, mepivacaine, propoxycaine, dyclonine, pramoxine, mepivacaine, procaine, chloroprocaine, ropivacaine, dibucaine, and etidocaine, and mixtures thereof.
• Suitable preservatives include food-grade preservatives or preservative systems, such as sorbic acid and its salts, benzoic acid and its salts, calcium propionate, sodium nitrite, sodium nitrate, sulfites (such as sulfur dioxide, sodium bisulfite, and potassium hydrogen sulfite) disodium EDTA, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), tert-butyl hydroquinone (TBHQ), and propyl gallate.
• sorbic acid and its salts such as sorbic acid and its salts, benzoic acid and its salts, calcium propionate, sodium nitrite, sodium nitrate, sulfites (such as sulfur dioxide, sodium bisulfite, and potassium hydrogen sulfite) disodium EDTA, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), tert-butyl hydro
• Suitable antihistamines include diphenhydramine, which can provide anti-inflammatory benefits.
• Suitable corticosteroids include prednisone. Diphenhydramine and/or prednisone are contemplated as preferred ingredients for providing anti-inflammatory benefits.
• Suitable anti-microbial agents include chlorhexidine and peroxide compounds.
• Suitable antifungal agents include nystatin and amphotericin.
• Suitable food-grade hydrophilic polymers may include polyalkylene glycols such as polyethylene glycols, carbomers or other polymers of acrylic acid, and gums such as guar gum.
• the present compositions can include from 0.1% to 70% by weight, alternatively from 0.5% to 25% by weight, alternatively from 1% to 20% by weight, alternatively from 5% to 15% by weight, of the hydrophilic polymer, based on the total weight of the powder.
• the present disclosure also provides methods of preparing liquid compositions suitable for use in the treatment of oral injury, oral inflammation and/or oral pain.
• Suitable compositions are prepared as follows.
• a powder is combined and mixed with an appropriate volume of water to achieve the consistency desired.
• 538 mg of powder (or another amount) can be mixed with 30 ml (30 g) or 40 ml (40 g) or another suitable amount of water.
• Preferred weight ratios of powder to water include from about 0.005: 1 about 0.1 : 1, alternatively 0.01 : 1 to about 0.05: 1, alternatively about 0.015: 1 to about 0.02: 1.
• the present disclosure provides liquid compositions that are essentially free of visible particles or precipitates at the foregoing weight ratios of powder to water.
• the water can be distilled water, tap water, bottled water or water from another source.
• the powder can be packaged in a packet such as a tube, sachet, or other container.
• the packet can be essentially moisture impermeable, such as a foil
• the present disclosure also provides methods for treating oral wounds, oral mucotitis or inflammation, oral pain, xerostomia, chronic hyposalivation or complications therefrom.
• the methods comprise administering a liquid composition as described herein, for example, as a liquid oral rinse, to a subject in need of treatment.
• the oral inflammation, injury or pain arises from an infection to the mouth, including but not limited to candidiasis, moniliasis, reactivation of latent virus and secondary infections, septicaemia, and combinations thereof.
• the inflammation is part of the broader syndrome associated with oral mucositis, erythema, Sjogren's Syndrome and any combination thereof.
• the present methods can also be used for treatment of oral inflammation associated with immune-compromised patients including bone marrow transplant patients and AIDS patients, or associated with chemotherapy or radiation treatment.
• the present disclosure provides methods for treating xerostomia and/or chronic hyposalivation that arise as a medication side effect, dehydration, radiotherapy involving the salivary glands, or a disease.
• Medications with xerogenic side effects include antihistamines, antidepressants, anticholenergics, anorexiants, antihypertensives, antipsychotics, anti-Parkinson agents, diuretics and sedatives.
• xerostomia diseases that cause xerostomia include Sjogren's Syndrome, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, diabetes mellitus, hypertension, cystic fibrosis, and diseases of the salivary gland.
• Complications of xerostomia and/or chronic hyposalivation include tooth decay, dental caries, oral candidiasis, dysgeusia, oral dysesthesia, and others.
• the present methods can be used for the prevention and treatment of dysphagia and/or stomatitis.
• the methods comprise administering a liquid composition as described herein, for example, as a liquid oral rinse, to a subject in need of treatment.
• Salivary pH in a subject suffering from xerostomia is commonly acidic, having a pH of
• S. mutans bacteria thrive in an acidic environment. In xerostomic patients it is not uncommon to see elevated levels of S. mutans bacteria, often exceeding 500,000 colony-forming units (CFU). Elevated levels of S. mutans increase the risk for dental caries. Buffering the salivary pH can modulate and/or reduce the levels of S. mutans to lower levels (such as less than
• the present disclosure provides methods for modulating the average salivary pH in the oral cavity of a subject in need of such modulation, such as a subject suffering from xerostomia and/or chronic hyposalivation, by administering a liquid composition as described herein to such a subject.
• the average salivary pH is raised at least 0.3 pH units, alternatively at least 0.5 pH units, alternatively at least 0.7 pH units, alternatively at least 1 pH unit, alternatively at least 1.2 pH unit.
• the average salivary pH is raised to at least 6, alternatively at least 6.2, alternatively at least 6.5, alternatively at least 6.6, alternatively at least 6. 7, alternatively at least 6.8, alternatively at least
• the present disclosure provides methods for balancing or reducing microtlora, such as S. mutans bacteria, by administering a liquid composition as described herein to a subject in need of treatment.
• a liquid composition as described herein to a subject in need of treatment.
• the S. mutans population in the oral cavity of a subject can be reduced from greater than 500,000 cfu/ml to less than 500,000 cfu/ml, alternatively less than 350,000 cfu/ml, alternatively less than 200,000 cfu/ml.
• the liquid compositions are designed to be physiologically compatible with both intact and compromised tissue in the mouth, and will alleviate pain associated with all types of injury to the mucosal tissue of the mouth and oral cavity.
• the pH and osmotic pressure of the compositions can be adjusted to be compatible with saliva, such as by including an appropriate amount of sodium bicarbonate, for example.
• sodium bicarbonate assists in balancing the pH and buffering of oral acids in the mouth.
• the present methods comprise admitting a liquid composition into a mouth of a subject in need of treatment, swirling or gargling the liquid composition, and expelling the liquid composition from the subject's mouth.
• the pH and osmotic pressure of the liquid composition can be adjusted to be compatible with saliva.
• Suitable pH ranges for the liquid composition comprise from 5.5 to 7.8, alternatively from 6 to 7.5, alternatively from 6.6 to 7.1, alternatively from 6.8 to 7.
• This example describes testing done to explore cause(s) of the formation of visible particles or precipitates that were seen at times in supersaturated oral rinses.
• Table 1 provides a description of the visual solubility tests performed using various components (including a commercial sample), with the quantities of each product weighed, and visual observations after the components were mixed in water. The tests were undertaken out of a desire to evaluate the cause of visible particles or precipitates that were seen, as avoiding the particles or precipitates could provide a more visually pleasing product though they do not cause any problems with the efficacy of the product.
• Test 12 the combination of dibasic sodium phosphate anhydrous and calcium chloride dihydrate
• Test 7 the combination of dibasic sodium phosphate anhydrous and calcium chloride dihydrate
• Calcium chloride from both sources, calcium glycerophosphate and calcium lactate gluconate salts were all found to be sufficiently soluble with a resulting pH of between 7.6 and 8.1.
• the calcium lactate gluconate salt has a lower calcium content versus other salts evaluated, so it may not be preferred for some embodiments.
• Tables 3 to 5 provide a description of the tests performed on combinations of different calcium sources, each table describing a different mix calcium and sodium phosphate salts. It was found that both calcium salts were incompatible with dibasic sodium phosphate at those concentrations. It was also found that glycerophosphate salt led to higher pH for the liquid composition.
• Example 4a was prepared as a reference blend with the components and percentages shown in Table 6. As expected, this formulation resulted in precipitation when mixed with 30 ml water at room temperature.
• Example 4b was prepared by reducing sodium chloride original quantity by 100 mg (from 404.11 mg to 304.11 mg), giving a final blend of powder of 438.0 mg instead of 538.0 mg. The components and their amounts are shown in Table 7. This formulation also yielded precipitation when mixed with 30 ml water at room temperature. Table 7
• Example 4c was prepared by substituting the calcium chloride dihydrate salt used in original formula by calcium glycerophosphate salt without dibasic sodium phosphate (Table 9). Without dibasic sodium phosphate, the dispersion produced was turbid but no particles in suspension and visible precipitate were observed.
• Example 4d was prepared by adding dibasic sodium phosphate anhydrous to ingredients used for Example 4c (Table 10). The phosphates level was reduced. This experiment showed the improved compatibility of calcium glycerophosphate compared to calcium chloride with dibasic sodium phosphate, as the dispersion produced was turbid but no particles in suspension and visible precipitates were observed. Table 9
• Example 4e is presented in Table 10, and it was prepared by reducing sodium bicarbonate ratio and increasing dibasic and monobasic sodium phosphates ratios (to their original ratios like Example 4a). The pH obtained was closer to 7.0. This formulation was considered promising as the phosphate and calcium contents are equivalent to the original Neutrasal formulation, and as the dispersion produced was turbid but no particles in suspension and no visible precipitate were observed.
• Example 4f was prepared by reducing the amounts of the two sodium phosphate salts and increasing calcium glycerophosphate ratio compared to Example 4f (Table 11). The objective was to obtain ratios of 22,000 to 25,000 ppm calcium ions and 65,000 to 70,000 ppm phosphate ions (as phosphate) per package.
• Example 4e The pH obtained was slightly higher than Example 4e at 7.23, but still with the 6.5-7.5 acceptable range.
• the dispersion produced was slightly turbid but less so than Example 4e. Table 11
• Example 4f is especially consistent with the objectives of a calcium ion content between about 22,000 and about 25,000 ppm, a phosphate ion content between about 65,000 and about 70,000 ppm and pH between about 6.5 and about 7.5. More particularly, it has a calculated calcium ion content of 22,923 ppm and a calculated phosphate ion content of 69,944 ppm (as phosphate). Both are calculated based on weight percentages of solid components in the powder.
• calcium lactate gluconate can be used in place of calcium glycerophosphate, except that the amounts of calcium lactate gluconate should be increased to about 2.1 fold of the amount of calcium glycerophosphate in order to obtain substantially the same calcium content in the powder or liquid.
• the specification also provides a description of methods of using any of those compositions in the described methods.
• the methods of manufacture described in the specification it is intended that the specification also provides a description of the manufacture of any of the compositions described herein.
• Ranges can be expressed as from “about” one particular value, and/or to "about” another particular value. When such a range is expressed, another aspect includes the one particular value and/or to exactly the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about,” it will be understood that the particular value forms another aspect and is disclosed by the present inventors. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “ 10" is disclosed, then “about 10" is also disclosed.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Inorganic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Cosmetics (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=56125518

Family Applications (1)

Country Status (10)

Cited By (2)

Families Citing this family (2)

Citations (2)

Family Cites Families (32)

• 2015
  • 2015-11-19 US US14/945,865 patent/US11590165B2/en active Active
  • 2015-12-15 WO PCT/CA2015/051327 patent/WO2016095036A1/en not_active Ceased
  • 2015-12-15 EP EP15868778.0A patent/EP3233092B1/en active Active
  • 2015-12-15 KR KR1020177019831A patent/KR102397070B1/ko active Active
  • 2015-12-15 AU AU2015367208A patent/AU2015367208B2/en active Active
  • 2015-12-15 CA CA2971224A patent/CA2971224C/en active Active
  • 2015-12-15 CN CN201580075768.8A patent/CN107530374B/zh active Active
  • 2015-12-15 BR BR112017013158-7A patent/BR112017013158B1/pt active IP Right Grant
  • 2015-12-15 MX MX2017007741A patent/MX372952B/es active IP Right Grant
  • 2015-12-15 JP JP2017533337A patent/JP6781701B2/ja active Active
• 2023
  • 2023-02-24 US US18/113,939 patent/US20230241102A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events